Shendong Yuan

发表

Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.

M. Adler, M. Whitlow, C. Mallari, 2018, Bioorganic & medicinal chemistry letters.

Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).

M. Adler, M. Whitlow, R. Pulk, 2009, Bioorganic & medicinal chemistry letters.

Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1*

Marc Adler, M. Adler, M. Whitlow, 2005, Journal of Biological Chemistry.

Structures of potent selective peptide mimetics bound to carboxypeptidase B.

M. Adler, M. Whitlow, J. Morser, 2008, Acta crystallographica. Section D, Biological crystallography.

A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models

C. Mallari, R. Vergona, W. Dole, 2007, Thrombosis and Haemostasis.

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.

J. Morser, I. Islam, Shendong Yuan, 2008, Thrombosis research.

Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.

M. Adler, M. Whitlow, R. Feldman, 2007, Bioorganic & medicinal chemistry letters.

Potent Triazolothione Inhibitor of Heat‐Shock Protein‐90

M. Adler, M. Whitlow, R. Feldman, 2009, Chemical biology & drug design.

Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process.

Wei Xu, M. Morrissey, I. Islam, 2018, Bioorganic & medicinal chemistry letters.

249 Novel small molecule inhibitors of 3′-phosphoinositide-dependent kinase-1 (PDK-1)

R. Feldman, B. Alicke, M. Polokoff, 2004 .

Total Synthesis of Covalent Cysteine Protease Inhibitor N-Desmethyl Thalassospiramide C and Crystallographic Evidence for Its Mode of Action.

M. Adler, Shendong Yuan, K. Emayan, 2019, Organic letters.

A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) – Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis

R. Vergona, M. Nagashima, W. Dole, 2006, Thrombosis and Haemostasis.

1-(1,3-Benzodioxol-5-ylmethyl)-3-[4-(1H-imidazol-1-yl)phenoxy]-piperidine analogs as potent and selective inhibitors of nitric oxide formation.

Wei Xu, M. Adler, M. Whitlow, 2007, Bioorganic & medicinal chemistry letters.

Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.

Paul Beroza, Zhao Ren, Dean R Artis, 2013, Bioorganic & medicinal chemistry letters.

Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B.

M. Adler, M. Whitlow, I. Islam, 2005, Biochemistry.

A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) – Part I: Pharmacological characterization

R. Vergona, M. Nagashima, J. Morser, 2006, Thrombosis and Haemostasis.

3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).

M. Adler, M. Whitlow, R. Vergona, 2007, Bioorganic & medicinal chemistry letters.

Design and synthesis of thiophene dihydroisoquinolines as novel BACE1 inhibitors.

P. Beroza, Jiangli Yan, H. Sham, 2013, Bioorganic & medicinal chemistry letters.

Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.

H. Sham, L. Latimer, M. Bova, 2013, Bioorganic & medicinal chemistry letters.

Development of a Novel β-Secretase Binding Assay Using the AlphaScreen Platform

H. Cheung, H. Sham, M. Bova, 2013, Journal of biomolecular screening.